NASDAQ:FLXN - Flexion Therapeutics Stock Price, Price Target & More

Flexion Therapeutics trades on the NASDAQ under the ticker symbol "FLXN."

Flexion Therapeutics Inc (NASDAQ:FLXN) posted its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported ($1.10) EPS for the quarter, beating analysts' consensus estimates of ($1.33) by $0.23. The specialty pharmaceutical company had revenue of $2.19 million for the quarter, compared to analysts' expectations of $1.99 million. View Flexion Therapeutics' Earnings History.

9 Wall Street analysts have issued 1-year price targets for Flexion Therapeutics' stock. Their predictions range from $36.00 to $570.00. On average, they expect Flexion Therapeutics' share price to reach $98.8889 in the next year. This suggests a possible upside of 265.3% from the stock's current price. View Analyst Ratings for Flexion Therapeutics.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Flexion Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Flexion Therapeutics include Array Biopharma (ARRY), OPKO Health (OPK), Ironwood Pharmaceuticals (IRWD), Amicus Therapeutics (FOLD), The Medicines (MDCO), Ascendis Pharma A/S (ASND), Horizon Pharma (HZNP), Evotec (EVTCY), Intercept Pharmaceuticals (ICPT), Supernus Pharmaceuticals (SUPN), Heron Therapeutics (HRTX), Blueprint Medicines (BPMC), Emergent Biosolutions (EBS), Portola Pharmaceuticals (PTLA) and Akcea Therapeutics (AKCA).

Media headlines about FLXN stock have trended somewhat positive this week, according to Accern. Accern scores the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Flexion Therapeutics earned a media sentiment score of 0.13 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 46.42 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the next several days.

Flexion Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.77%) and Berson & Corrado Investment Advisors LLC (0.03%). Company insiders that own Flexion Therapeutics stock include Frederick W Driscoll, Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Institutional Ownership Trends for Flexion Therapeutics.

FLXN stock was sold by a variety of institutional investors in the last quarter, including Berson & Corrado Investment Advisors LLC. View Insider Buying and Selling for Flexion Therapeutics.

FLXN stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. Company insiders that have bought Flexion Therapeutics stock in the last two years include Mark Stejbach, Michael D Clayman, Neil Bodick, Samuel D Colella and Yamo Deniz. View Insider Buying and Selling for Flexion Therapeutics.

Shares of FLXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of FLXN stock can currently be purchased for approximately $27.07.

Flexion Therapeutics has a market capitalization of $1.02 billion and generates $350,000.00 in revenue each year. The specialty pharmaceutical company earns $-137,480,000.00 in net income (profit) each year or ($4.16) on an earnings per share basis. Flexion Therapeutics employs 251 workers across the globe.

Flexion Therapeutics' mailing address is 10 MALL ROAD SUITE 301, BURLINGTON MA, 01803. The specialty pharmaceutical company can be reached via phone at 781-305-7777 or via email at [email protected]